<DOC>
	<DOCNO>NCT00886158</DOCNO>
	<brief_summary>Viral infection important complication transplantation . Immunosuppressive therapy interfere T cell immunity result high incidence viral infection . Newer agent , mycophenolate mofetil ( MMF ) sirolimus , associate increase risk herpes virus infection . The introduction potent immunosuppressive agent past decade correlate increase rate hospitalization transplant patient infection . This prospective study determine role sub-clinical herpes virus infection development complication chronic allograft nephropathy ( CAN ) Post Transplant Lymphoproliferative Disease ( PTLD ) . By focus treatable herpes virus infection , study potential identify therapeutic strategy use diminish burden graft loss CAN , significantly improve renal allograft survival quality life transplant patient . Future specific intervention test hypothesis direct causal relationship sub-clinical herpes virus infection CAN may include use anti-viral therapy response sub-clinical infection renal allograft and/or peripheral blood .</brief_summary>
	<brief_title>Virus Surveillance Pediatric Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Age birth 21 year All solid organ transplant recipient receive care Seattle Children 's Hospital Signed consent , age appropriate , sign assent Lack consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Organ Transplants</keyword>
</DOC>